Vor Biopharma (NYSE:VOR) Earns “Outperform” Rating from Wedbush

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a research note issued to investors on Thursday,RTT News reports. They presently have a $7.00 price target on the stock.

A number of other analysts have also recently commented on VOR. HC Wainwright reiterated a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $10.79.

Vor Biopharma Trading Up 0.9 %

Shares of VOR stock traded up $0.01 during mid-day trading on Thursday, reaching $0.85. The stock had a trading volume of 242,997 shares, compared to its average volume of 593,730. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $2.43. The company has a market cap of $58.51 million, a P/E ratio of -0.52 and a beta of -0.40. The business has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.01.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. increased its holdings in shares of Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after acquiring an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in Vor Biopharma during the 4th quarter valued at approximately $707,000. Two Sigma Investments LP boosted its position in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after purchasing an additional 25,930 shares during the period. Northern Trust Corp boosted its position in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after purchasing an additional 44,252 shares during the period. Finally, Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma during the 4th quarter valued at approximately $102,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.